BrainsWay (ADR) Logo
US10501L1061
A2PCBP
BWAY

BrainsWay (ADR)

Wczytywanie kursów wyceny...

Prognoza

Średnia cena docelowa analityków wynosi 17,73 € (+108,34%). Mediana wynosi 17,73 € (+108,34%).

Kupuj
  7
Trzymaj
  1
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • BrainsWay beats revenue forecasts in Q2 2026 and raises full-year outlook

    BrainsWay reported revenue of $17.1 million in Q2 2026, beating analysts’ estimate of $16.31 million; adjusted earnings per share were $0.07, in line with expectations. The company raised its 2026 revenue guidance to $68–70 million and recorded revenue growth of 35% year over year along with more than a fourfold increase in operating income. Gross margin remained steady at 75%, adjusted EBITDA was positive for the twelfth consecutive quarter, and the installed system base rose to around 1,950 units. Management cites strong demand for Deep TMS and the SWIFT protocol, as well as reimbursements covering about 57 million insured people, as drivers. » Więcej na de.investing.com


  • BrainsWay invests $3 million in Radial Health

    BrainsWay has acquired a $3 million minority stake in Radial Health as part of a Series A financing round. Radial operates a network of brain-medicine clinics and develops clinical infrastructure, reimbursement tools, and an AI-supported decision platform for non-invasive therapies such as Deep TMS. The capital will be used to expand clinical presence, strengthen the technology platform and evaluate M&A opportunities; BrainsWay describes the investment as part of a strategy to acquire minority stakes in mental health care providers. » Więcej na de.investing.com


  • BrainsWay: US insurers allow psychiatric nurse practitioners to provide TMS treatment

    A growing number of US insurers, including Optum/United Behavioral Health, have allowed psychiatric nurse practitioners in full-practice states since the end of 2025 to prescribe, supervise and administer transcranial magnetic stimulation (TMS) for commercial plans covering about 34.8 million enrollees. Other payers and providers such as First Coast, National Government Services, Novitas, the VA and TRICARE West have introduced similar reimbursement models, subject to regulatory requirements. BrainsWay sees this as an opportunity to improve access to deep TMS and shorten waiting times; the stock reacted positively and is trading near its 52-week high after a 258% gain last year. » Więcej na de.investing.com


  • BrainsWay invests additional $6 million in Neurolief after FDA premarket clearance

    BrainsWay closes a milestone-based convertible note of $6 million as a second tranche for Neurolief after Neurolief received FDA premarket clearance for the Proliv™Rx system. With this, BrainsWay has invested a total of $11 million in Neurolief; a third tranche of up to $5 million is possible if a revenue-based target is met. BrainsWay also holds a purchase option on all outstanding shares of Neurolief, with the price tied to a fixed company valuation or a revenue multiple. Parallel to the financing, Neurolief is expanding provider access by adding an authorized distributor to the U.S. Department of Veterans Affairs supplier list. » Więcej na de.investing.com


  • BrainsWay: Highmark plans expanded reimbursement for accelerated Deep‑TMS protocol

    Highmark Blue Cross Blue Shield has issued a draft policy to expand reimbursement for BrainsWay’s accelerated SWIFT‑Deep‑TMS protocol for adolescents and adults with major depressive disorder. After a public comment period, the rule is expected to take effect in February 2026 and covers a five‑times‑daily, 10‑minute program over six days plus follow‑up sessions (38 sessions in total). The FDA approved the protocol in September 2025; data showed a response rate of 87.8% and a remission rate of 78.0%, prompting BrainsWay to anticipate broader market acceptance. » Więcej na de.investing.com

Dane finansowe spółki

W ostatnim kwartale BrainsWay (ADR) osiągnęła przychody w wysokości 15,89 mln € i zysk netto w wysokości 1,95 mln €
(EUR) wrzesień 2026
YoY
Przychody 15,89 mln 37,99%
Zysk brutto 12,38 mln 42,96%
Zysk netto 1,95 mln 45,79%
EBITDA 2,68 mln 13,12%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
360,6 mln €
Liczba akcji
39,22 mln
Maksimum/minimum z 52 tygodni
15,82 € - 4,58 €
Dywidendy Nie
Beta
0,15
C/Z (PE Ratio)
38,94
PEG (PEG Ratio)
0,62
C/WK (PB Ratio)
4,90
C/S (PS Ratio)
5,83

Profil spółki

Brainsway Ltd. opracowuje i sprzedaje nieinwazyjne terapie neurostymulacyjne w leczeniu zaburzeń psychicznych w Stanach Zjednoczonych, Europie, Izraelu oraz na innych rynkach międzynarodowych. Oferuje technologię platformy Deep Transcranial Magnetic Stimulation (głęboka przezczaszkowa stymulacja magnetyczna) stosowaną w leczeniu dużej depresji, depresji lękowej, zaburzeń obsesyjno-kompulsyjnych, uzależnienia od palenia tytoniu, zaburzeń dwubiegunowych, zespołu stresu pourazowego, schizofrenii, choroby Alzheimera, autyzmu, przewlekłego bólu, stwardnienia rozsianego, rehabilitacji po udarze oraz choroby Parkinsona. Firma działa przede wszystkim z lekarzami, szpitalami i ośrodkami medycznymi w dziedzinie psychiatrii. Brainsway Ltd. została założona w 2003 roku i ma siedzibę w Jerozolimie w Izraelu.

Nazwa
BrainsWay (ADR)
CEO
Hadar Levy
Siedziba Jerusalem, jm
Izrael
Strona internetowa
Sektor
Ochrona zdrowia
Branża
Ochrona zdrowia: sprzęt i produkty
Debiut giełdowy
17.12.2018
Pracownicy 129

Symbole giełdowe

Giełda Symbol
NASDAQ
BWAY
🍪

Parqet  używa plików cookie. Dowiedz się więcej